The introduction of UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium) reflects a key milestone for the brand. A landmark, 4-year global trial in chronic obstructive pulmonary disease (COPD), UPLIFT® is evaluating the potential of tiotropium to slow disease progression by reducing the rate of decline in lung function.
UPLIFT® Overview
| Duration: | 4 years |
|---|---|
| Results expected: | 2nd half 2008 |
| Clinical outcome: | Reduction in rate of decline in lung function in COPD patients? |
| PLUS usual care: | All respiratory medication except inhaled anticholinergics |
| Lead investigator: | Professor Marc Decramer Respiratory Division University Hospitals Katholieke Universiteit Leuven, Belgium |
6,000 patients from 37 countries recruited to groundbreaking UPLIFT study corporate news archive
Sponsored by Boehringer Ingelheim and Pfizer Inc., UPLIFT® is assessing the long-term effects of tiotropium on lung-function decline, health-related quality of life, exacerbations and associated hospitalisations and mortality (respiratory and all-cause). A post-hoc analysis of data from two 1-year studies showed that patients had a rate of decline in lung function parameter through FEV1 of 12 ml/year compared with 58 ml/year for placebo, thus positively supporting the scientific rationale underlying UPLIFT®.
